Request Demo
Last update 11 Jul 2025
Shanghai Enkai Cell Technology Co. Ltd.
Joint Venture Company | Private Company | Subsidiary Company|2020|Shanghai Shi, China|
Joint Venture Company | Private Company | Subsidiary Company|2020|Shanghai Shi, China|
Last update 11 Jul 2025
Overview
Basic Info
Introduction NK CellTech Co., Ltd., also known as Unicar-Therapy, operates as a biotechnological entity concentrating on the advancement of innovative cellular immunotherapy technology. Anchored by the mission to tackle major clinical therapeutic challenges, Unicar-Therapy is dedicated to delivering precise immunotherapeutic solutions and has developed an array of proprietary, intelligent natural killer (NK) cell products. |
Tags
Neoplasms
Other Diseases
Infectious Diseases
Immune cell therapy
Fusion protein
Bispecific antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
NCT06773091
An Open-Label, Single-Arm, Multicenter Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of NK042 Cell Injection (Universal NKR+NK) in Advanced Solid Tumors
CTR20244839
评价NK042细胞注射液（通用型NKR+NK）在晚期实体瘤中的安全性、初步疗效的开放、单臂、多中心I期临床研究
[Translation] An open, single-arm, multicenter Phase I clinical study to evaluate the safety and preliminary efficacy of NK042 cell injection (universal NKR+NK) in advanced solid tumors
100 Clinical Results associated with Shanghai Enkai Cell Technology Co. Ltd.
Login to view more data
Login to view more data
100 Deals associated with Shanghai Enkai Cell Technology Co. Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Enkai Cell Technology Co. Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 18 Jul 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
5
6
Preclinical
IND Approval
1
1
Phase 1
Other
2
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free